Combined Evaluation of Expression of CXCR4 and Nrf2 as Prognostic Factor for Patients with Gastric Carcinoma

Author(s): Shuo Yu, Tao Wu, Jia Wang, Chuantao Cheng, Jing Wang, Liangzhang Sun, Chao Liu, Gang Cao*, Tinghua Hu*.

Journal Name: Anti-Cancer Agents in Medicinal Chemistry

Volume 18 , Issue 3 , 2018

Submit Manuscript
Submit Proposal

Graphical Abstract:


Abstract:

Background: CXC Chemokine Receptor 4 (CXCR4) and NFE–related factor 2 (Nrf2) have been observed implicated with cell malignant behavior of human cancers.

Aims: In this study, we detected their expression in gastric carcinoma (GC) tissue specimens and related the result with clinicopathological data and patient survival.

Methods: 120 GC and compared normal tissue specimens were processed to analyse the expression of CXCR4 and Nrf2. We found that the expression of CXCR4 and Nrf2 was dramatically increased in GC tissues when compared to the distant non-cancer tissues (P<0.05). CXCR4 overexpression was associated with the depth of invasion (P= 0.006) Histological grade (P=0.018) TNMstage (P= 0.021) lymph node metastasis (P < 0.001) and distant metastasis (P=0.026), whereas overexpression of Nrf2 protein was significantly associated with tumor size (P=0.045), Histological grade (P=0.026), TNMstage (P= 0.020), lymph node metastases (P < 0.001) and distant metastasis (P=0.008). Furthermore, we observed a significant co-expression of CXCR4 and Nrf2 expression in GC specimens.

Results: In the survival part, we found that GC patients with CXCR4+ and Nrf2+ had worse outcomes. The significant prognostic indicators are age, tumor size, histological grade, TNMstage, CXCR4, Nrf2, and coexpression of CXCR4 and Nrf2 in GC patients. Multivariate analysis showed that TNMstage and CXCR4+/Nrf2+ expression were risk factors. Above all we come to the conclusion that the expression of CXCR4 might partly be regulated by the level of Nrf2 and both positive expressions suggest poor prognosis of GC patients.

Keywords: CXCR4, Nrf2, gastric carcinoma, clinicopathological, biomarker, prognostic.

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 18
ISSUE: 3
Year: 2018
Page: [388 - 393]
Pages: 6
DOI: 10.2174/1871520617666171103112019
Price: $58

Article Metrics

PDF: 29
HTML: 3